Anticardiolipin antibodies in patients with cancer: A case–control study
Authors
Nipu, Md Ashraful IslamKundu, Shoumik
Alam, Sayeda Sadia
Dina, Ashrafun Naher
Hasan, MD Ashraful
Khan, Mohammad
Khalil, Md Ibrahim
Hossan, Tareq
Islam, Md Asiful
Issue Date
2023-03-31
Metadata
Show full item recordAbstract
Antiphospholipid antibodies are highly prevalent in autoimmune diseases and mainly associated with thromboembolic events, which is one of the major reasons for cancer-related mortality. Confirmed adult cancer patients were included (n = 40) with an equal number of age- and sex-matched healthy controls. The presence and concentration of anticardiolipin antibodies were investigated by the enzyme-linked immunosorbent assay using the venous blood samples. aCL antibodies were detected in 60.0% (n = 24) of the cancer patients compared to none in the healthy controls (p < 0.001). The serum concentration of aCL antibodies was significantly higher in cancer patients than controls (p < 0.001) and ranged from 89.0 U/mL to 133.0 U/mL among the aCL-positive patients. All the lung cancer patients (n = 6) were diagnosed with positive aCL, and a borderline significant association of aCL antibody positivity was observed in colon cancer patients (p = 0.051). About 72.7% of the advanced-stage cancer individuals and 81.8% of the cancer patients who underwent surgery were diagnosed with positive aCL antibodies. A significant association of aCL antibody positivity was observed with cancer patients comorbid with heart diseases (p = 0.005). The prevalence and serum levels of aCL antibodies were significantly higher in cancer patients compared to healthy controls. Cancer patients (i.e., lung, liver, and colon), at advanced-stage, comorbid with heart diseases, who underwent surgery, were more likely to be diagnosed with aCL antibodies.Citation
Nipu, M.A.I.; Kundu, S.; Alam, S.S.; Dina, A.N.; Hasan, M.A.; Khan, M.; Khalil, M.I.; Hossan, T.; Islam, M.A. Anticardiolipin Antibodies in Patients with Cancer: A Case–Control Study. Cancers 2023, 15, 2087. https://doi.org/10.3390/cancers15072087Publisher
MDPI AGJournal
CancersPubMed ID
37046748 (pubmed)Additional Links
https://www.mdpi.com/2072-6694/15/7/2087Type
Journal articleLanguage
enDescription
© 2023 The Authors. Published by MDPI. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.3390/cancers15072087EISSN
2072-6694Sponsors
This research was funded by National Science and Technology Fellowship 2019–2020, Bangladesh. The open-access publication was supported by the University of Birmingham, Birmingham B15 2TT, UK.ae974a485f413a2113503eed53cd6c53
10.3390/cancers15072087
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Licence for published version: Creative Commons Attribution 4.0 International
Related articles
- Anticardiolipin Antibodies in Patients with Cancer: A Case-Control Study.
- Authors: Nipu MAI, Kundu S, Alam SS, Dina AN, Hasan MA, Khan M, Khalil MI, Hossan T, Islam MA
- Issue date: 2023 Mar 31
- The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases.
- Authors: Merkel PA, Chang Y, Pierangeli SS, Convery K, Harris EN, Polisson RP
- Issue date: 1996 Dec
- Prevalence and clinical correlation of anti-phospholipid-binding protein antibodies in anticardiolipin-negative patients with systemic lupus erythematosus and women with unexplained recurrent miscarriages.
- Authors: Bizzaro N, Tonutti E, Villalta D, Tampoia M, Tozzoli R
- Issue date: 2005 Jan
- APhL antibody ELISA as an alternative to anticardiolipin test for the diagnosis of antiphospholipid syndrome.
- Authors: Suh-Lailam BB, Cromar A, Davis KW, Tebo AE
- Issue date: 2012